BrainStorm Cell Therapeutics Inc. Receives United States Patent Office Notice Of Allowance For Its Stem Cell Technology
1/13/2014 10:12:00 AM
NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has received a Notice of Allowance from the U.S. Patent Office for its "Isolated Cells and Populations Comprising Same for the Treatment of CNS Diseases" (serial number 11/727,583) patent application.
Help employers find you! Check out all the jobs and post your resume.
comments powered by